New hope for Tough-to-Treat lung cancers: trial tests pill to slow tumor growth
NCT ID NCT04010357
Summary
This study is testing an oral drug called Abemaciclib for people with specific, aggressive types of lung cancer that have stopped responding to or returned after standard chemotherapy. The goal is to see if the drug can safely shrink tumors and slow the cancer's progression. It is for adults with small cell or other high-grade neuroendocrine lung cancers that have a specific genetic marker (Rb wild-type).
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106-5065, United States
Conditions
Explore the condition pages connected to this study.